UK first country to secure zero-tariff US pharmaceuticals deal
New trade deal to “ignite economic growth” and help boost the UK’s position as a superpower in life sciences.
List view / Grid view
New trade deal to “ignite economic growth” and help boost the UK’s position as a superpower in life sciences.
EPR Issue 4 includes articles on manufacturing, AI/ML, vaccine development, biologics and more.
New BSI standard PAS 2090 could reshape how the pharmaceutical industry reports and minimises its environmental footprint.
Changes proposed in the EU body’s regulatory framework aim to create a competitive and sustainable European bioeconomy.
Swiss pharma company to trim production of oral medicines and packaging in Stein, while boosting productivity in Schweizerhalle.
Nippon Muki illustrates the superiority of its innovative HEPA filter as a tool for sterilising injectable containers during the manufacturing process.
The move is part of biopharma's $50 billion pledge to US medicines manufacturing and R&D.
The companies’ partnership covers messenger RNA design and production services.
R&D projects supported by the Centre for Process Innovation (CPI) aim to shape a sustainable, resilient and competitive future for pharma manufacturing.
The expansion places the pharma company’s full manufacturing loop in the US under one roof.
The pharmaceutical laboratory meeting adds sessions on AI in labs, and quality in biologics, mRNA and analytics.
As well as the new safety warnings for the Duchenne muscular dystrophy gene therapy, the biopharma company also faced a new, more restrictive licence for the treatment.
By utilising patient-derived instead of donor-derived platelets, the method could offer a safer approach to platelet transfusions.
He joins from contract development and manufacturing organisation Porton Pharma Solutions.
The German pharma company’s agreement for its South Korea sites is the latest green initiative to be unveiled by the industry.